OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Cell-free expression shows promise in preclinical applications but presents scale-up challenges.
Demand for recombinant microorganism-based cell culture supplements.
Biopharma responds to demand dynamics for upstream bioprocessing capacity.
October 02, 2020
An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.
Bioreactor technology advances can offer seamless manufacturing scale-up and can reduce the timeline and cost of biologics production.
September 03, 2020
This article will explore the traditional path from the laboratory to the clinic and how the fixed-bed technology provides an alternative solution to meet commercial demands.
August 02, 2020
Process modeling offers an opportunity to troubleshoot for and anticipate difficult aspects of a bioprocess.
July 02, 2020
Innovative approaches, including ready-to-use materials and in-line dilution, can significantly streamline overall bioprocessing operations.
June 01, 2020
Therapies for early and late treatment and passive immunization of COVID-19 are needed and can be developed using antibodies from recovered patients.
May 01, 2020
Synthetic biology has advanced the scope and scale with which biologically derived therapeutics can be developed.
April 03, 2020
New bioreactor designs, coupled with better media, process intensification and analytics, continue to improve upstream bioprocessing.
March 09, 2020
The new BIOSTAT STR Generation 3 with BIOBRAIN bioproduction platform offers process intensification with automated feed and bleed and integrated cell retention functionality.
March 02, 2020
Better understanding and control of cell behavior is yielding benefits, upstream and beyond.